DJIA 16,374.76 23.38 0.14%
NASDAQ 4,733.50 -16.48 -0.35%
S&P 500 1,951.13 2.27 0.12%
market minute promo

10.20 0.05 (0.49%)

Quote as of

Extended Hours: $10.20 $0.00 (0.00%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

MACK $10.20 0.49%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $10.17
Previous Close $10.15
Daily Range $10.11 - $10.47
52-Week Range $6.38 - $13.84
Market Cap $1.1B
P/E Ratio -11.40
Dividend (Yield) $0.00 (0.0%)
Volume 1,448,243
Average Daily Volume 1,470,714
Current FY EPS -$1.06

Sector

Healthcare

Industry

Drug Makers

Merrimack Pharmaceuticals, Inc. (MACK) Description

Merrimack Pharmaceuticals Inc is a biopharmaceutical company discovering developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases with an initial focus on cancer. Website: http://www.merrimackpharma.com/

News & Commentary Rss Feed

Why Merrimack Pharmaceuticals Inc is Soaring Today

Investors cheer a smaller than expected loss and wait patiently for news about regulatory approval of MM-398.

Merrimack Pharmaceuticals (MACK) Is Today's Dead Cat Bounce Stock

10 Biotech Stocks With Catalysts Coming Soon

Friday 8/14 Insider Buying Report: SHLM, MACK

Merrimack Pharmaceuticals (MACK) Catches Eye: Stock Up 5.8%

Merrimack Pharmaceuticals' Q2 Loss Wider, Revenues Up - Analyst Blog

Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q2 2015 Results - Earnings Call Transcript

Earnings Reaction History: Merrimack Pharmaceuticals Inc, 25.0% Follow-Through Indicator, 7.2% Sensi

Earnings Reaction History: Merrimack Pharmaceuticals Inc, 25.0% Follow-Through Indicator, 7.2% Sensitive

Merrimack Pharmaceuticals (MACK): Q2 Earnings Preview - Analyst Blog

Merrimack Pharmaceuticals' Stock Tanked in July: Is It Now a Buy?

Shares of Merrimack Pharmaceuticals slumped in July by double digits. Does this huge dip represent a compelling buying opportunity?

See More MACK News...